-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Camrelizumab in Bile Duct Cancer (Cholangiocarcinoma)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Camrelizumab in Bile Duct Cancer (Cholangiocarcinoma) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Camrelizumab in Bile Duct Cancer (Cholangiocarcinoma) Drug Details: Camrelizumab (Airuika)...
-
Product Insights
United Kingdom (UK) SME Insurance Market Size, Trends, Competitor Dynamics and Opportunities
United Kingdom (UK) SME Insurance Market Report Overview Despite the significant economic challenges faced by small and medium-sized enterprises (SMEs) in recent years, the number of SMEs still increased in the UK in 2023. This growth highlights the importance of these companies as a source of business growth in the commercial insurance sector. Since SME switching behavior has increased, insurers should offer cheaper or more affordable policies. The UK SME insurance market research report presents information on the leading insurers...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – GEN-1047 in Endometrial Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - GEN-1047 in Endometrial Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. GEN-1047 in Endometrial Cancer Drug Details: GEN-1047 is under development for...
-
Product Insights
Ludji
Ludji is a Hydro project located in Racha-Lechkhumi and Kvemo Svaneti, Georgia. The project is owned by Georgian Co-Investment Fund; RB Insurance Group LLC. The project is at the permitting stage. Empower your strategies with our Ludji report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business day of the purchase, excluding weekends and holidays. Certain sections of the report may...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Cerewint in Alzheimer’s Disease
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Cerewint in Alzheimer's Disease report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Cerewint in Alzheimer's Disease Drug Details: Cerewint (RB-ADSC) is under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Dimethyltryptamine in Treatment Resistant Depression
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Dimethyltryptamine in Treatment Resistant Depression report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Dimethyltryptamine in Treatment Resistant Depression Drug Details:Dimethyltryptamine (DMT) is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – HM-3 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - HM-3 in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. HM-3 in Solid Tumor Drug Details: HM-3 is under development for...
-
Thematic Analysis
Demographics in Banking – Thematic Intelligence
Demographics in Banking Thematic Report Overview Demographic mega-trends around birth rates, migration, and aging are intersecting with rising geo-political tensions, de-globalization, inflation, and a host of other social will have profound implications for the development of financial services across the value chain. The following are some of the key highlights of the demographics in banking theme analysis report: The single biggest demographic shift for incumbent banks will likely be the inversion in provider preferences. In the US, for example, customers...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ETH-155008 in Relapsed Acute Myeloid Leukemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ETH-155008 in Relapsed Acute Myeloid Leukemia report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.ETH-155008 in Relapsed Acute Myeloid Leukemia Drug Details:ETH-155008 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AAA-603 in Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AAA-603 in Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.AAA-603 in Human...